News
2.11.23

TOPADUR, Yonsei University and Juvic Inc. grant awarded

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

Download DocumentDokument herunterladen
5.1.24
Press Release

Topadur Pharma AG receives an innosuisse grant

CHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers

Read more
27.10.20
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
7.4.22
Press Release

TOPADUR in collaboration with USZ / UZH was awarded CHF 605k by Innosuisse

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.

Read more